- Home
- TRSG vs BNR Comparison
TRSG vs BNR Comparison
Compare TRSG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- BNR
- Stock Information
- Founded
- TRSG 1996
- BNR 2014
- Country
- TRSG Singapore
- BNR China
- Employees
- TRSG N/A
- BNR N/A
- Industry
- TRSG
- BNR Medical Specialities
- Sector
- TRSG
- BNR Health Care
- Exchange
- TRSG NYSE
- BNR Nasdaq
- Market Cap
- TRSG 27.0M
- BNR 38.3M
- IPO Year
- TRSG 2024
- BNR 2020
- Fundamental
- Price
- TRSG $1.72
- BNR $6.47
- Analyst Decision
- TRSG
- BNR
- Analyst Count
- TRSG 0
- BNR 0
- Target Price
- TRSG N/A
- BNR N/A
- AVG Volume (30 Days)
- TRSG 6.2K
- BNR 53.8K
- Earning Date
- TRSG 05-14-2025
- BNR 08-21-2025
- Dividend Yield
- TRSG N/A
- BNR N/A
- EPS Growth
- TRSG N/A
- BNR N/A
- EPS
- TRSG N/A
- BNR N/A
- Revenue
- TRSG $12,810,249.00
- BNR $72,112,038.00
- Revenue This Year
- TRSG N/A
- BNR $136.32
- Revenue Next Year
- TRSG N/A
- BNR N/A
- P/E Ratio
- TRSG N/A
- BNR N/A
- Revenue Growth
- TRSG N/A
- BNR 0.53
- 52 Week Low
- TRSG $1.00
- BNR $2.18
- 52 Week High
- TRSG $4.57
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- BNR 60.79
- Support Level
- TRSG N/A
- BNR $5.81
- Resistance Level
- TRSG N/A
- BNR $9.48
- Average True Range (ATR)
- TRSG 0.00
- BNR 0.90
- MACD
- TRSG 0.00
- BNR 0.12
- Stochastic Oscillator
- TRSG 0.00
- BNR 45.86
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.